Tirzepatide

Dual GLP-1 + GIP Agonist

R 3 070,50/ penMost effective

The most effective weight-loss compound studied to date. Tirzepatide targets both the GLP-1 and GIP receptors simultaneously, producing superior appetite suppression and metabolic improvement — averaging 22.5% weight reduction in clinical trials.

ConcentrationTirzepatide 21.67mg / 2.6ml

Dosage2.5mg–5.4mg once a week

Pen strength

Check eligibility →Ask a pharmacist

Prescription medicine — dispensed only after doctor approval. Payment is held until your protocol is approved.

Prescription-only compounded medicine, dispensed only after a doctor reviews your assessment. Store refrigerated (2–8°C).

Key benefits

See the science +

Simultaneous GLP-1 and GIP agonism delivers additive metabolic benefits beyond what single-receptor agonists achieve.

How to Use

A once-weekly subcutaneous injection via the pre-filled DOSIST pen, available in 5.4mg, 10.8mg and 16.3mg strengths. Your prescriber sets a structured titration schedule to keep side effects minimal.

Formulation

Sterile, pharmacy-compounded — Tirzepatide 21.67mg, 43.33mg or 65mg per 2.6ml pen, depending on strength.

Pharmacist-compounded

SAHPRA compliant

Doctor-reviewed

Cold-chain delivery